Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

Oncogene

Volumn 30, Issue 16, 2011, Pages 1963-1968

  Zhang, H ^a   Guttikonda, S ^a   Roberts, L ^a   Uziel, T ^a   Semizarov, D ^a   Elmore, S W ^a   Leverson, J D ^a   Lam, L T ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Bcl xL; Mcl 1; NSCLC

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; COMPLEMENTARY DNA; OLIGONUCLEOTIDE; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN NOXA; SMALL INTERFERING RNA;

3' UNTRANSLATED REGION; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DEATH; CELL SURVIVAL; CYTOTOXICITY; GENE SILENCING; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 79955468507     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.559     Document Type: Article

References (26)

1. Akgul C. (2009). Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 66: 1326-1336.
2. Berrieman HK, Smith L, O'Kane SL, Campbell A, Lind MJ, Cawkwell L. (2005). The expression of Bcl-2 family proteins differs between nonsmall cell lung carcinoma subtypes. Cancer 103: 1415-1419. (Pubitemid 40410737)
3. Borner MM, Brousset P, Pfanner-Meyer B, Bacchi M, Vonlanthen S, Hotz MA et al. (1999). Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer 79: 952-958. (Pubitemid 29082132)
4. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393-403. (Pubitemid 40193310)
5. Chen S, Dai Y, Harada H, Dent P, Grant S. (2007). Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67: 782-791. (Pubitemid 46192219)
6. Cory S, Huang DC, Adams JM. (2003). The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590-8607. (Pubitemid 38028528)
7. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
8. Keuling AM, Felton KE, Parker AA, Akbari M, Andrew SE, Tron VA. (2009). RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS One 4: e6651.
9. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2: 183-192. (Pubitemid 41043974)
10. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. (2004). Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6: 443-450. (Pubitemid 38607505)
11. Li J, Viallet J, Haura EB. (2008). A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol 61: 525-534. (Pubitemid 350275989)
12. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA et al. (2007). 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26: 3972-3979. (Pubitemid 46884293)
13. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S. (2009). Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 6: 352-366.
14. Minna JD, Roth JA, Gazdar AF. (2002). Focus on lung cancer. Cancer Cell 1: 49-52. (Pubitemid 41039175)
15. Reed JC, Doctor KS, Godzik A. (2004). The domains of apoptosis: a genomics perspective. Sci STKE 2004: re9.
16. Rodenhuis S, Slebos RJ. (1992). Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52: 2665s-22669s.
17. Song L, Coppola D, Livingston S, Cress D, Haura EB. (2005). Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther 4: 267-276. (Pubitemid 41351285)
18. Sun S, Schiller JH, Spinola M, Minna JD. (2007). New molecularly targeted therapies for lung cancer. J Clin Invest 117: 2740-2750. (Pubitemid 47529602)
19. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Bock BC et al. (2008). Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27: 6646-6656.
20. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J et al. (2007). Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 67: 1176-1183.
21. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. (2008). ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421-3428.
22. Wesarg E, Hoffarth S, Wiewrodt R, Kroll M, Biesterfeld S, Huber C et al. (2007). Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer 121: 2387-2394. (Pubitemid 350022407)
23. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. (2005). Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305. (Pubitemid 41003019)
24. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. (2007). Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859.
25. Zhai D, Jin C, Huang Z, Satterthwait AC, Reed JC. (2008). Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J Biol Chem 283: 9580-9586.
26. Zhang B, Gojo I, Fenton RG. (2002). Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99: 1885-1893. (Pubitemid 34525465)